Clinical Trial Update: The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effectiveness of alemtuzumab combined with CHOP in newly diagnosed peripheral T-cell lymphoma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Mahidol University | Conditions: Peripheral T-Cell Lymphoma | Phase 2 | Status: TERMINATED